

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
UAF Technologies and Research, LLC	08/04/2008
RECEIVING PARTY DATA	
Name:	Arisyn Therapeutics, Inc.
Street Address:	401 Rosemont Avenue
Internal Address:	3rd Floor, Rosenstock Hall
City:	Frederick
State/Country:	MARYLAND
Postal Code:	21701
PROPERTY NUMBERS Total: 43	
Property Type	Number
Application Number:	11212300
Application Number:	11204707
Patent Number:	5767138
Patent Number:	6262093
Patent Number:	6265427
Patent Number:	6552059
Patent Number:	6984654
Patent Number:	6077862
Patent Number:	6482843
Patent Number:	6420411
Patent Number:	6864275
Patent Number:	6423736
Patent Number:	6900235
Patent Number:	6710065

PATENT

500614321

REEL: 021339 FRAME: 0769

OP \$1720.00 11212300

Patent Number:	6407131
Patent Number:	6423735
Patent Number:	6506783
Patent Number:	6906091
Patent Number:	6423734
Patent Number:	6384049
Patent Number:	6407105
Patent Number:	6930121
Patent Number:	6462062
Patent Number:	6720349
Patent Number:	6380232
Patent Number:	6916836
Patent Number:	6608096
Patent Number:	6362207
Patent Number:	6479526
Patent Number:	6653335
Patent Number:	6177460
Patent Number:	5629341
Patent Number:	5656615
Patent Number:	6498188
Patent Number:	6258831
Patent Number:	6410575
Patent Number:	6245788
Patent Number:	6384064
Patent Number:	6340696
Patent Number:	6194430
Patent Number:	6392052
Patent Number:	6297384
Patent Number:	7022712

CORRESPONDENCE DATA

Fax Number: (310)807-9701

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 310-807-9700

Email: trademarkprosecution@ztllp.com

Correspondent Name: Joel Ginsberg

Address Line 1: 10866 Wilshire
Address Line 4: Los Angeles, CALIFORNIA 90024

ATTORNEY DOCKET NUMBER: 1112-1001

NAME OF SUBMITTER: Joel B. Ginsberg

Total Attachments: 14

source=UAF Technologies Patent Assignment#page1.tif
source=UAF Technologies Patent Assignment#page2.tif
source=UAF Technologies Patent Assignment#page3.tif
source=UAF Technologies Patent Assignment#page4.tif
source=UAF Technologies Patent Assignment#page5.tif
source=UAF Technologies Patent Assignment#page6.tif
source=UAF Technologies Patent Assignment#page7.tif
source=UAF Technologies Patent Assignment#page8.tif
source=UAF Technologies Patent Assignment#page9.tif
source=UAF Technologies Patent Assignment#page10.tif
source=UAF Technologies Patent Assignment#page11.tif
source=UAF Technologies Patent Assignment#page12.tif
source=UAF Technologies Patent Assignment#page13.tif
source=UAF Technologies Patent Assignment#page14.tif

Patent Assignment for Recording

For good and valuable consideration, the receipt of which is hereby acknowledged, and subject to the terms and conditions set forth in that certain Purchase, Sale and Assignment Agreement (the "Agreement") dated as of August 4, 2008, by and between UAF Technologies & Research, L.L.C., an Arizona limited liability company, having an address at 1111 N. Cherry Avenue, Tucson, AZ 85721 ("Assignor"), and Arisyn Therapeutics, Inc., a Delaware corporation, having an address at 401 Rosemont Avenue, 3rd Floor, Rosenstock Hall, Frederick, MD 21701 ("Assignee"), Assignor has sold, assigned, and transferred and does hereby sell, assign, and transfer to Assignee, for itself and its successors, transferees, and assignees, the following:

The entire worldwide right, title and interest in any and all inventions and improvements that are disclosed in the United States Letters Patents (the "Assigned Patents") set forth on **Attachment I** attached hereto.

Assignor further agrees to do the following, when requested, and without further consideration, in order to carry out the intent of this assignment/agreement:

- (1) execute any and all oaths, assignments, powers of attorney, applications, and other papers necessary or desirable to fully secure to Assignee the rights, titles and interests herein conveyed;
- (2) communicate to Assignee all known facts relating to the Assigned Patents; and
- (3) generally do all lawful acts that Assignee shall consider desirable for securing, maintaining and enforcing worldwide patent protection relating to the content of the Assigned Patents and for vesting in Assignee the rights, titles and interests herein conveyed.

Assignor represents that Assignor has the rights, titles and interests to convey, as set forth herein and covenants with Assignee that Assignor has not made and will not make any other assignment, grant, mortgage, license or other agreement affecting the rights, titles and interests herein conveyed.

This assignment may be executed in one or more counterparts, each of which shall be deemed an original and all of which may be taken together as one and the same assignment.

Date: August 4, 2008

FOR ASSIGNOR:

UAF Technologies and Research, L.L.C.

By: Alfred P. Statham
Alfred P. Statham, Manager

FOR ASSIGNEE:

Arisyn Therapeutics, Inc.

By: _____
Eric Zucco, President

Patent Assignment for Recording

For good and valuable consideration, the receipt of which is hereby acknowledged, and subject to the terms and conditions set forth in that certain Purchase, Sale and Assignment Agreement (the "Agreement") dated as of August 4, 2008, by and between UAF Technologies & Research, L.L.C., an Arizona limited liability company, having an address at 1111 N. Cherry Avenue, Tucson, AZ 85721 ("Assignor"), and Arisyn Therapeutics, Inc., a Delaware corporation, having an address at 401 Rosemont Avenue, 3rd Floor, Rosenstock Hall, Frederick, MD 21701 ("Assignee"), Assignor has sold, assigned, and transferred and does hereby sell, assign, and transfer to Assignee, for itself and its successors, transferees, and assignees, the following:

The entire worldwide right, title and interest in any and all inventions and improvements that are disclosed in the United States Letters Patents (the "Assigned Patents") set forth on **Attachment I** attached hereto.

Assignor further agrees to do the following, when requested, and without further consideration, in order to carry out the intent of this assignment/agreement:

- (1) execute any and all oaths, assignments, powers of attorney, applications, and other papers necessary or desirable to fully secure to Assignee the rights, titles and interests herein conveyed;
- (2) communicate to Assignee all known facts relating to the Assigned Patents; and
- (3) generally do all lawful acts that Assignee shall consider desirable for securing, maintaining and enforcing worldwide patent protection relating to the content of the Assigned Patents and for vesting in Assignee the rights, titles and interests herein conveyed.

Assignor represents that Assignor has the rights, titles and interests to convey, as set forth herein and covenants with Assignee that Assignor has not made and will not make any other assignment, grant, mortgage, license or other agreement affecting the rights, titles and interests herein conveyed.

This assignment may be executed in one or more counterparts, each of which shall be deemed an original and all of which may be taken together as one and the same assignment.

Date: August 4, 2008

FOR ASSIGNOR:

UAF Technologies and Research, L.L.C.

By: _____
Alfred P. Statham, Manager

FOR ASSIGNEE:

Arisyn Therapeutics, Inc.

By: Eric Zucco
Eric Zucco, President

**ATTACHMENT I
TO
EXHIBIT B
(ASSIGNED PATENTS)**

[Please see the attached]

WSM No.	UTR No.	Country	Pat. No./ Date	App. No./ Date	Title
45251-P010D1		US	5,767,138 06/16/1998	08/771,193 12/20/1996	Pharmaceutical Composition for Inhibiting the Growth of Viruses and Cancers
45252-P010D2P1		US	6,262,093 07/17/2001	09/264,942 03/09/1999	Methods of Treating Cancer with Benzimidazoles
45252-P010WECH		CH	0821586 06/11/2003	96910803.4 04/11/1996	A Pharmaceutical Composition Containing Benzimidazole for Inhibiting the Growth of Cancers
45252-P010WEDE		DE	69628645.9 06/11/2003	96910803.4 04/11/1996	A Pharmaceutical Composition Containing Benzimidazole for Inhibiting the Growth of Cancers
45252-P010WEFR		FR	0821586 06/11/2003	96910803.4 04/11/1996	A Pharmaceutical Composition Containing Benzimidazole for Inhibiting the Growth of Cancers
45252-P010WEGB		UK	0821586 06/11/2003	96910803.4 04/11/1996	A Pharmaceutical Composition Containing Benzimidazole for Inhibiting the Growth of Cancers
45252-P010WEIT		IT	0821586 06/11/2003	96910803.4 04/11/1996	A Pharmaceutical Composition Containing Benzimidazole for Inhibiting the Growth of Cancers
45252-P010WENL		NL	0821586 06/11/2003	96910803.4 04/11/1996	A Pharmaceutical Composition Containing Benzimidazole for Inhibiting the Growth of Cancers
45252-P010WJPD1		JP		2007- 176633 07/04/2007	A Pharmaceutical Composition Containing Benzimidazole for Inhibiting the Growth of Cancers
		AU	714078 03/30/2000	53897/96 04/11/1996	A Pharmaceutical Composition Containing Benzimidazole for Inhibiting the Growth of Cancers
45252-P010WOCA		CA	2217952 06/25/2002	2217952 04/11/1996	A Pharmaceutical Composition Containing Benzimidazole for Inhibiting the Growth of Cancers

WSM No.	UTR No.	Country	Pat. No./ Date	App. No./ Date	Title
45252-P010WOEP		EP	0821586 06/11/2003	96910803.4 04/11/1996	A Pharmaceutical Composition Containing Benzimidazole for Inhibiting the Growth of Cancers
45252-P010WOJP		JP		531152/1996 04/11/1996	A Pharmaceutical Composition Containing Benzimidazole for Inhibiting the Growth of Cancers
45252-P010WOMX		MX		977809 04/11/1996	A Pharmaceutical Composition Containing Benzimidazole for Inhibiting the Growth of Viruses and Cancers
45252-P010WONZ		NZ	305784 07/12/2001	305784 04/11/1996	A Pharmaceutical Composition Containing Benzimidazole for Inhibiting the Growth of Cancers
45252-P011P1		US	6,265,427 07/24/2001	09/375,173 08/16/1999	Pharmaceutical Composition for and Method of Treating Leukemia
45252-P011P1C1		US	6,552,059 04/22/2003	09/792,112 02/23/2001	Pharmaceutical Composition for and Method of Treating Leukemia
45252-P012C1		US	6,984,654 01/10/2006	10/340,945 01/13/2003	Cancer Treatments and Pharmaceutical Compositions Therefor
45252-P012C2		US		11/212,300 08/26/2005	Cancer Treatments and Pharmaceutical Compositions Therefor
45252-P012D1		US	6,077,862 06/20/2000	09/259,969 03/01/1999	Virus and Cancer Treatments
45252-P012P1		US	6,482,843 11/19/2002	09/676,407 09/29/2000	Compounds and Methods for Use Thereof in the Treatment of Cancer or Viral Infections
45252-P012P10		US	6,420,411 07/16/2002	09/676,202 09/29/2000	Compounds and Methods for Use Thereof in the Treatment of Cancer or Viral Infections
45252-P012P2		US	6,864,275 03/08/2005	09/676,034 09/29/2000	Compounds and Methods for Use Thereof in the Treatment of Cancer

WSM No.	UTR No.	Country	Pat. No./ Date	App. No./ Date	Title
45252-P012P4		US	6,423,736 07/23/2002	09/676,409 09/29/2000	Compounds and Methods for Use Thereof in the Treatment of Cancer or Viral Infections
45252-P012P5		US	6,900,235 05/31/2005	09/676,032 09/29/2000	Benzimidazole Compounds, and Pharmaceutical Compositions and Unit Dosages Thereof
45252-P012P6		US	6,710,065 03/23/2004	09/676,031 09/29/2000	Compounds and Methods for Use Thereof in the Treatment of Cancer
45252-P012P7		US	6,407,131 06/18/2002	09/676,030 09/29/2000	Compounds and Methods for Use Thereof in the Treatment of Cancer or Viral Infections
45252-P012P8		US	6,423,735 07/23/2002	09/676,029 09/29/2000	Compounds and Methods for Use Thereof in the Treatment of Cancer or Viral Infections
45252-P012US		US	6,506,783 01/14/2003	08/857,811 05/16/1997	Cancer Treatments and Pharmaceutical Compositions Therefor
45252-P012WEGB		UK	0956017 06/06/2007	97949600.7 11/26/1997	Benzimidazole-2-Carbamates for the Treatment of Viral Infections
45252-P012WEIE		IE	0956017 06/06/2007	97949600.7 11/26/1997	Benzimidazole-2-Carbamates for the Treatment of Viral Infections
45252-P012WELU		LU	0956017 06/06/2007	97949600.7 11/26/1997	Benzimidazole-2-Carbamates for the Treatment of Viral Infections
45252-P012WOAU		AU	728690 05/03/2001	74027/98 11/26/1997	Benzimidazole-2-Carbamates for the Treatment of Viral Infections and Cancer
45252-P012WOCA		CA	2268840 10/03/2006	2268840 11/26/1997	Benzimidazole-2-Carbamates for the Treatment of Viral Infections and Cancer
45252-P012WOEP		EP	0956017 06/06/2007	97949600.7 11/26/1997	Benzimidazole-2-Carbamates for the Treatment of Viral Infections

WSM No.	UTR No.	Country	Pat. No./ Date	App. No./ Date	Title
45252-P012WOJP		JP		521930/1998 11/26/1997	Benzimidazole-2-Carbamates for the Treatment of Viral Infections and Cancer
45252-P012WO AUD1		AU	763272 11/06/2003	37094/01 04/18/2001	Benzimidazole-2-Carbamates for the Treatment of Viral Infections and Cancer
45252-P012WOMX		MX		993320 11/26/1997	Benzimidazole-2-Carbamates for the Treatment of Viral Infections and Cancer
45252-P012WONZ		NZ	335159 01/10/2002	335159 11/26/1997	Benzimidazole-2-Carbamates for the Treatment of Viral Infections and Cancer
45252-P013C1		US	6,906,091 06/14/2005	10/198,334 07/18/2002	Method of Cancer Treatment
45252-P013US		US	6,423,734 07/23/2002	09/374,717 08/13/1999	Method of Preventing Cancer
45252-P013WECH		CH	1202735 10/13/2004	00952534.6 08/04/2000	The Use of a Benzimidazole in the Preparation of a Medicament for the Prevention of Cancer
45252-P013WEDE		DE	1202735 10/13/2004	00952534.6 08/04/2000	The Use of a Benzimidazole in the Preparation of a Medicament for the Prevention of Cancer
45252-P013WEFR		FR	1202735 10/13/2004	00952534.6 08/04/2000	The Use of a Benzimidazole in the Preparation of a Medicament for the Prevention of Cancer
45252-P013WEGB		UK	1202735 10/13/2004	00952534.6 08/04/2000	The Use of a Benzimidazole in the Preparation of a Medicament for the Prevention of Cancer
45252-P013WENL		NL	1202735 10/13/2004	00952534.6 08/04/2000	The Use of a Benzimidazole in the Preparation of a Medicament for the Prevention of Cancer
45252-P013WOAU		AU	763311 10/30/2003	65210/00 08/04/2000	Method of Cancer Treatment

WSM No.	UTR No.	Country	Pat. No./ Date	App. No./ Date	Title
45252-P013WOCA		CA	2380414 06/13/2006	2380414 08/04/2000	Method of Cancer Treatment
45252-P013WOEP		EP	1202735 10/13/2004	00952534.6 08/04/2000	The Use of a Benzimidazole in the Preparation of a Medicament for the Prevention of Cancer
45252-P013WOMX		MX	234662 03/06/2006	2002/00157 1 08/04/2000	Method of Cancer Treatment
45252-P013WONZ		NZ	516766 03/09/2004	516766 08/04/2000	Method of Preventing Cancer
45252-P014US		US	6,384,049 05/07/2002	09/578,281 05/25/2000	Cancer Treatment
45252-P015US		US	6,407,105 06/18/2002	09/670,169 09/26/2000	Compounds and Methods for Use Thereof in the Treatment of Cancer or Viral Infections
45252-P015WOAU		AU	2001292796 04/06/2006	2001292796 09/19/2001	Compounds and Methods for Use Thereof in the Treatment of Cancer or Viral Infections
45252-P015WOCA		CA		2422916 09/19/2001	Compounds and Methods for Use Thereof in the Treatment of Cancer or Viral Infections
45252-P015WOEP		EP		01973190.0 09/19/2001	Benzimidazoles and Methods for Use Thereof in the Treatment of Cancer or Viral Infections
45252-P015WOJP		JP		2002- 531100 09/19/2001	Benzimidazoles and Methods for Use Thereof in the Treatment of Cancer or Viral Infections
45252-P015WOMX		MX	242143 11/21/2006	2003/00260 1 09/19/2001	Compounds and Methods for Use Thereof in the Treatment of Cancer or Viral Infections

WSM No.	UTR No.	Country	Pat. No./ Date	App. No./ Date	Title
45252-P016D1		US	6,930,121 08/16/2005	10/267,051 10/08/2002	Compounds and Methods for Use Thereof in the Treatment of Viral Infections
45252-P016D2		US		11/204,707 08/16/2005	Compounds and Methods for Use Thereof in the Treatment of Cancer
45252-P016US		US	6,462,062 10/08/2002	09/670,168 09/26/2000	Compounds and Methods for Use Thereof in the Treatment of Cancer or Viral Infections
45252-P017D1		US	6,720,349 04/13/2004	10/132,545 04/25/2002	Compounds and Methods for Use Thereof in the Treatment of Cancer or Viral Infections
45252-P017US		US	6,380,232 04/30/2002	09/670,170 09/26/2000	Benzimidazole Urea Derivatives, and Pharmaceutical Compositions and Unit Dosages Thereof
45252-P018D1		US	6,916,836 07/12/2005	10/634,542 08/05/2003	Compounds and Methods for Use Thereof in the Treatment of Viral Infections
45252-P018US		US	6,608,096 08/19/2003	09/670,166 09/26/2000	Compounds and Methods for Use Thereof in the Treatment of Cancer or Viral Infections
45252-P010D2 P1D1		US	6,362,207 03/26/2002	09/748,651 12/22/2000	Methods of Treating Viral Infections with Benzimidazoles
45252-P010D2 PDC1		US	6,479,526 11/12/2002	10/106,429 03/26/2002	Pharmaceutical Composition for Inhibiting the Growth of Viruses and Cancers
45252-P010D2 PDC2		US	6,653,335 11/25/2003	10/288,264 11/06/2002	Pharmaceutical Composition for Inhibiting the Growth of Viruses and Cancers
45251-P001D1P2		US	6,177,460 01/23/2001	09/408,664 09/29/1999	Method of Treatment for Cancer or Viral Infections
45251-P001US		US	5,629,341 05/13/1997	08/420,913 04/12/1995	Pharmaceutical Composition for Inhibiting the Growth of Viruses and Cancers

WSM No.	UTR No.	Country	Pat. No./ Date	App. No./ Date	Title
45251-P001WAU D1		AU	730920 07/05/2001	22315/00 03/15/2000	A Pharmaceutical Composition Containing N-Chlorophenylcarbarnates and N-Chlorophenylthiocarbarnates for Inhibiting the Growth of Viruses and Cancers
45251-P001WOAU		AU	714056 03/30/2000	53898/96 04/11/1996	A Pharmaceutical Composition Containing N-Chlorophenylcarbarnates and N-Chlorophenylthiocarbarnates for Inhibiting the Growth of Viruses and Cancers
45251-P001WOCA		CA	2217953 12/04/2001	2217953 04/11/1996	A Pharmaceutical Composition Containing N-Chlorophenylcarbarnates and N-Chlorophenylthiocarbarnates for Inhibiting the Growth of Viruses and Cancers
45251-P001WOEP		EP	0820281 07/25/2007	96910804.2 04/11/1996	A Pharmaceutical Composition Containing N-Chlorophenylcarbarnates and N-Chlorophenylthiocarbarnates for Inhibiting the Growth of Viruses
45251-P001WEGB		UK	0820281 07/25/2007	96910804.2 04/11/1996	A Pharmaceutical Composition Containing N-Chlorophenylcarbarnates and N-Chlorophenylthiocarbarnates for Inhibiting the Growth of Viruses
45251-P001WEIE		IE	0820281 07/25/2007	96910804.2 04/11/1996	A Pharmaceutical Composition Containing N-Chlorophenylcarbarnates and N-Chlorophenylthiocarbarnates for Inhibiting the Growth of Viruses

WSM No.	UTR No.	Country	Pat. No./ Date	App. No./ Date	Title
45251-P001WELU		LU	0820281 07/25/2007	96910804.2 04/11/1996	A Pharmaceutical Composition Containing N-Chlorophenylcarbamates and N-Chlorophenylthiocarbamates for Inhibiting the Growth of Viruses
45251-P001WOJP		JP		531153/1996 04/11/1996	A Pharmaceutical Composition Containing N-Chlorophenylcarbamates and N-Chlorophenylthiocarbamates for Inhibiting the Growth of Viruses and Cancers
45251-P001WOMX		MX		97-7808 04/11/1996	A Pharmaceutical Composition Containing N-Chlorophenylcarbamates and N-Chlorophenylthiocarbamates for Inhibiting the Growth of Viruses and Cancers
45251-P001WONZ		NZ	305785 02/05/2002	305785 04/11/1996	A Pharmaceutical Composition Containing N-Chlorophenylcarbamates and N-Chlorophenylthiocarbamates for Inhibiting the Growth of Viruses and Cancers
45251-P002US		US	5,656,615 08/12/1997	08/420,935 04/12/1995	Pharmaceutical Composition for Inhibiting the Growth of Cancers and Viruses in Mammals
45251-P001D1P2 D1		US	6,498,188 12/24/2002	09/645,427 08/24/2000	Methods of Treatment for Cancer or Viral Infections
45251-P020P1		US	6,258,831 07/10/2001	09/535,172 03/27/2000	Viral Treatment
45251-P020PID1		US	6,410,575 06/25/2002	09/812,094 03/19/2001	Viral Treatment
45251-P020WECH		CH	1165070 06/15/2005	00921515.3 03/29/2000	Thiadiazolyl Urea or Thiourea Derivatives for Antiviral Treatment

WSM No.	UTR No.	Country	Pat. No./ Date	App. No./ Date	Title
45251-P020WEDE		DE	60020820 06/15/2005	00921515.3 03/29/2000	Thiadiazolyl Urea or Thiourea Derivatives for Antiviral Treatment
45251-P020WEFR		FR	1165070 06/15/2005	00921515.3 03/29/2000	Thiadiazolyl Urea or Thiourea Derivatives for Antiviral Treatment
45251-P020WEGB		UK	1165070 06/15/2005	00921515.3 03/29/2000	Thiadiazolyl Urea or Thiourea Derivatives for Antiviral Treatment
45251-P020WOAU		AU	763573 11/06/2003	41822/00 03/29/2000	Thiadiazolyl Urea or Thiourea Derivatives for Antiviral Treatment
45251-P020WOCA		CA	2368615 01/02/2007	2368615 03/29/2000	Thiadiazolyl Urea or Thiourea Derivatives for Antiviral Treatment
45251-P020WOEP		EP	1165070 06/15/2005	00921515.3 03/29/2000	Thiadiazolyl Urea or Thiourea Derivatives for Antiviral Treatment
45251-P020WOJP		JP		2000- 607629 03/29/2000	Thiadiazolyl Urea or Thiourea Derivatives for Antiviral Treatment
45251-P020WOMX		MX	224429 11/06/2004	2001/00988 9 03/29/2000	Thiadiazolyl Urea or Thiourea Derivatives for Antiviral Treatment
45251-P021P1		US	6,245,788 06/12/2001	09/535,173 03/27/2000	Viral Treatment
45251-P021P1C1		US	6,384,064 05/07/2002	09/871,565 05/30/2001	Viral Treatment
45251-P021P1P1		US	6,340,696 01/22/2002	09/663,578 09/15/2000	Viral Treatment

WSM No.	UTR No.	Country	Pat. No./ Date	App. No./ Date	Title
45251- P021WECH		CH	1165074 05/26/2004	00919867.2 03/29/2000	Viral Treatment
45251- P021WEDE		DE	60011060 05/26/2004	00919867.2 03/29/2000	Viral Treatment
45251- P021WEFR		FR	1165074 05/26/2004	00919867.2 03/29/2000	Viral Treatment
45251- P021WEGB		UK	1165074 05/26/2004	00919867.2 03/29/2000	Viral Treatment
45251- P021WOAU		AU	763275 10/30/2003	2001/00988 7 03/29/2000	Viral Treatment
45251- P021WOCA		CA	2368650 09/13/2005	2368650 03/29/2000	Viral Treatment
45251- P021WOEP		EP	1165074 05/26/2004	00919867.2 03/29/2000	Viral Treatment
45251-P021WOJP		JP		2000- 607620 03/29/2000	Viral Treatment
45251- P021WOMX		MX	224329 11/29/2004	2001/00988 7 03/29/2000	Viral Treatment
45251-P022P1		US	6,194,430 02/27/2001	09/538,006 03/29/2000	Viral Treatment
45251- P022WEDE		DE	60021065 06/29/2005	00919868.0 03/29/2000	Viral Treatment

WSM No.	UTR No.	Country	Pat. No./ Date	App. No./ Date	Title
45251-P022WEFR		FR	1165077 06/29/2005	00919868.0 03/29/000	Viral Treatment
45251-P022WEGB		UK	1165077 06/29/2005	00919868.0 03/29/000	Viral Treatment
45251-P022WOAU		AU	763431 11/06/2003	40489/00 03/29/2000	Viral Treatment
45251-P022WOCA		CA	2365495 01/02/2007	2365495 03/29/2000	Viral Treatment
45251-P022WOEP		EP	1165077 06/29/2005	00919868.0 03/29/2000	Viral Treatment
45251-P022WOJP		JP		2000- 607621 03/29/2000	Viral Treatment
45251-P022WOMX		MX	226557 03/03/2005	2001/00988 6 03/29/2000	Viral Treatment
45251-P023C1		US	6,392,052 05/21/2002	09/794,968 02/27/2001	Process for the Preparation of 1,2,4-Thiadiazoles
45251-P023US		US	6,297,384 10/02/2001	09/468,039 12/21/1999	Process for the Preparation of 1,2,4-Thiadiazoles
		US	7,022,712 04/04/06	10/402,347 03/26/03	Solubilization of weak bases